Latest Conference Articles

May 2nd 2020, 8:23pm

PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

May 2nd 2020, 6:00pm

PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.

April 30th 2020, 2:39am

AACR Annual Meeting

COM701, a novel, first-in-class immune checkpoint inhibitor, was found to demonstrate encouraging preliminary antitumor activity and good tolerability when used as either a monotherapy and in combination with nivolumab in a number of heavily pretreated patients with advanced or metastatic solid tumors, according to data from a phase 1 trial.

April 30th 2020, 2:29am

AACR Annual Meeting

Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.

April 30th 2020, 2:25am

AACR Annual Meeting

The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.

April 29th 2020, 8:46pm

AACR Annual Meeting

Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.

April 29th 2020, 4:11am

AACR Annual Meeting

A cell-free DNA test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas study presented at the 2020 AACR Virtual Annual Meeting I.

April 29th 2020, 3:45am

AACR Annual Meeting

Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population.

April 29th 2020, 3:40am

AACR Annual Meeting

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

April 29th 2020, 2:40am

AACR Annual Meeting

Paolo A. Ascierto, MD, discussed lessons he has learned from the COVID-19 crisis both in the melanoma treatment paradigm and in the broader immuno-oncology spectrum.

April 29th 2020, 2:22am

AACR Annual Meeting

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

April 29th 2020, 1:52am

AACR Annual Meeting

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

April 29th 2020, 1:45am

AACR Annual Meeting

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

April 29th 2020, 12:46am

AACR Annual Meeting

The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.

April 29th 2020, 12:43am

AACR Annual Meeting

Treating patients with cancer and coronavirus disease 2019 depends upon rapidly changing assessments of the standard of care as well as considerations of comorbidities and life expectancy.

April 29th 2020, 12:17am

AACR Annual Meeting

ECOG performance status, cancer type, and type of prior therapy received can predict risk for clinical worsening or death in patients with cancer who contract the coronavirus disease 2019.

April 28th 2020, 11:10pm

AACR Annual Meeting

Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.

April 28th 2020, 11:09pm

AACR Annual Meeting

Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).

April 28th 2020, 11:04pm

AACR Annual Meeting

Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

April 28th 2020, 5:56pm

AACR Annual Meeting

The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.